| DEFINIUM THERAPEUTICS |
| Kanada |
| Gesundheit |
| CA24477V1058 / A420P3 |
| MMQ0 (Frankfurt) / DFTX (NASDAQ) |
| FRA:MMQ0, ETR:MMQ0, MMQ0:GR, NASDAQ:DFTX |
| - |
| https://definiumtx.com/ |
|
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses..
>Volltext.. |
| 2327.48 Mio. EUR |
| 2039.9 Mio. EUR |
| - |
| -168.57 Mio. EUR |
| -207.07 Mio. EUR |
| -2.18 EUR |
| 35.54 Mio. EUR |
| 228.84 Mio. EUR |
| -126.44 Mio. EUR |
| 4.6 |
| - |
| -186.53% |
| - |
| - |
| - |
| - |
| DEFINIUM |
| 22.06.26 |
|